Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Status:
Completed
Trial end date:
2017-04-28
Target enrollment:
Participant gender:
Summary
Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in
average (with high variability) in the fourth decade. The disease progression is classically
characterized by a cognitive deterioration (cortical-frontal dementia), motor disorders
(associating chorea, dystonia and bradykinesia), psychiatric disturbances (combining
depression and irritability) and metabolic disorder (cachexia). The disease is fatal within
15 to 20 years in most patients. HD has no cure. Neuroleptics are the main drug used and the
only to demonstrate its efficacy on chorea in clinical trials. But neuroleptics have also
beneficial and adverse effects on other disease characteristics (motor, psychiatric,
cognitive or metabolic). Their profile between beneficial and adverse effects could be
different according the neuroleptics and their classification. The aim of this study is to
compare beneficial and adverse effects of 3 different neuroleptics in HD.